Axiom Investors LLC DE Takes $7.33 Million Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Axiom Investors LLC DE acquired a new position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 91,001 shares of the company’s stock, valued at approximately $7,327,000. Axiom Investors LLC DE owned approximately 0.17% of PROCEPT BioRobotics as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Signaturefd LLC increased its position in shares of PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after purchasing an additional 145 shares during the last quarter. Naviter Wealth LLC raised its holdings in shares of PROCEPT BioRobotics by 6.0% in the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company’s stock valued at $249,000 after purchasing an additional 176 shares during the period. Amundi lifted its position in shares of PROCEPT BioRobotics by 0.9% in the fourth quarter. Amundi now owns 20,143 shares of the company’s stock valued at $1,742,000 after buying an additional 183 shares during the last quarter. Arizona State Retirement System boosted its position in PROCEPT BioRobotics by 1.5% during the fourth quarter. Arizona State Retirement System now owns 14,285 shares of the company’s stock worth $1,150,000 after purchasing an additional 218 shares during the period. Finally, KRS Capital Management LLC grew its stake in PROCEPT BioRobotics by 0.5% in the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after buying an additional 225 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PRCT shares. Morgan Stanley cut their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company reissued an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $94.29.

PROCEPT BioRobotics Stock Down 2.8 %

Shares of NASDAQ PRCT opened at $60.05 on Monday. The company has a market cap of $3.29 billion, a price-to-earnings ratio of -30.79 and a beta of 1.05. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 12 month low of $45.56 and a 12 month high of $103.81. The stock has a 50-day moving average price of $65.34 and a two-hundred day moving average price of $77.82.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares of the company’s stock, valued at $9,875,374.20. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).